Company Overview and News

DoT clears Rs 4K-cr Idea-ATC tower deal

New Delhi : The Department of Telecom on Thursday cleared sale of standalone mobile towers of Idea Cellular for Rs 4,000 crore to the Indian arm of American Tower Corporation (ATC), according to official sources. “Idea-ATC deal has been cleared,” an official source said.

AMT / American Tower Corp. (REIT) 8-A12B


AMT / American Tower Corp. (REIT) 8-K (Current Report)


7 Triple-A Stocks to Buy — With 100% Street Support

2018-05-22 investorplace
Which top stocks are Wall Street analysts the most bullish on? Stocks with no “hold” or “sell” ratings and a pure “Strong Buy” analyst consensus. These are the stocks that make the most compelling investing opportunities and are definitely worth keeping a close eye on.

Undervalued Levered Equity Stub With "Ick Factor"

2018-05-22 seekingalpha
Altice NV (Altice Europe post spin ALVVF) plans on spinning off its US division (Altice USA) by the end of 2Q 2018. At todays prices, you would recover 83% of your investment in Altice NV with Altice USA shares by the second quarter after the spinoff. Altice Europe stub, which trades at a c.25% levered free cash flow yield, the lowest valuation in its history, is being priced like roadkill. By not going bankrupt and bringing its leverage down to 4x EBITDA, the heavily discounted shares of Altice Europe stub offer attractive upside potential with a significant margin of safety given the upcoming spin-off of Altice USA and upcoming divestitures of non-core assets.

REIT And Homebuilders Sink As Treasury Yields Climb

2018-05-19 seekingalpha
After rallying 6% over the past three weeks, REITs retreated by 3% this week as the 10-year yield climbed to it’s highest level since 2011. Homebuilders dipped nearly 2%.

7 Great Ways to Move Into Real Estate Investing

2018-05-18 investorplace
Real estate is an attractive investment category — and also a risky one. Owning physical real estate can provide attractive returns, but a lot can go wrong: tenants can leave in the middle of the night, pipes can burst and markets can change without warning.

AMT / American Tower Corp. (REIT) 424B2 (Prospectus)


5 Autonomous Driving Car Stocks That Aren't Tesla Inc | InvestorPlace

2018-05-16 investorplace
Self-driving cars are on the way — and investors are looking to profit. One popular choice in self-driving car stocks has been Tesla Inc (NASDAQ:TSLA), a potential play on the shift to both electric automobiles and autonomous driving. But with TSLA stock looking a bit shaky at the moment, investors might benefit from looking toward less well-covered — and less volatile — autonomous driving car stocks.

AMT / American Tower Corp. (REIT) FWP

FWP Issuer Free Writing Prospectus Filed pursuant to Rule 433 Registration Statement No. 333-211829 Final Term Sheet

Vodafone India posts Rs 9,805 crore operating profit for financial year 2017-18

New Delhi: Vodafone India today posted operating profit of Rs. 9,805 crore for the financial year 2017-18, ended March 31. It had reported a loss of around Rs 30,690 crore for 2016-17 on account of the UK-based Vodafone group cutting down valuation of Indian unit by taking gross impairment charge of 4.5 billion euro.

AMT / American Tower Corp. (REIT) 424B5 (Prospectus)

424B5 Table of Contents File pursuant to Rule 424(b)(5) Registration No. 333-211829 This preliminary prospectus supplement relates to an effective registration statement under the Securities Act of 1933, as amended, but is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus ar

Vodafone India posts Rs 9,805 cr operating profit for 2017-18

2018-05-15 moneycontrol
Vodafone India today posted operating profit of Rs 9,805 crore for the financial year 2017-18, ended March 31. It had reported a loss of around Rs 30,690 crore for 2016-17 on account of the UK-based Vodafone group cutting down valuation of Indian unit by taking gross impairment charge of 4.5 billion euro.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

22h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

22h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

CUSIP: 03027X100